Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1183

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 4
Chunk 1183
---
 to employees and further developing detailed policies and procedures.

We expect to remediate these material weaknesses
in the first half of 2025. However, there may be additional material weaknesses identified that could require additional time and resources
to remediate. We remain committed to ensuring that our internal control over financial reporting is designed and operating effectively.

Although we did not include an attestation report
of the independent registered public accounting firm in this Annual Report on Form 10-K, we acknowledge the deficiencies in our internal
control over financial reporting and are actively working towards remediation and improvement. We will continue to monitor and evaluate
the effectiveness of our internal control over financial reporting to ensure timely and accurate financial reporting.

Attestation Report on Internal Control
over Financial Reporting

This Annual Report on Form 10-K does not include
an attestation report of our independent registered public accounting firm due to the deferral allowed under the Jumpstart Our Business
Startups Act of 2012 for emerging growth companies.

Changes in Internal Control over Financial
Reporting

Other than with respect to the remediation efforts
discussed above, there was no change in our internal control over financial reporting that occurred during the year ended December 31,
2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

None.

Item 9C. Disclosure Regarding
Foreign Jurisdictions that Prevent Inspections.

Not applicable.

60

PART
III

Item 10. Directors, Executive
Officers, and Corporate Governance.

The following table sets forth the name, age
and position of each of our executive officers, directors and director nominees as of March 27, 2025.

    Name
     
    Age

    Position
     
    Director Since
  
    Geoffrey Dow
     
    51

    Chief Executive Officer, President and Director
     
    June 1, 2022
  
    Tyrone Miller
     
    50

    Chief Financial Officer

    Kristen Landon
     
    58

    Chief Commercial Officer

    Charles Allen
     
    49

    Director
     
    July 11, 2023
  
    Cheryl Xu
     
    57

    Director
     
    July 11, 2023
  
    Stephen Toovey
     
    71

    Director
     
    July 11, 2023
  
    Paul Field
     
    62